Log In
Print
BCIQ
Print
Print this Print this
 

Fraxiparine, nadroparin

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionLow molecular weight heparin
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacromolecule: Polysaccharide
Latest Stage of DevelopmentApproved
Standard IndicationThrombosis
Indication DetailsPrevent clots in placental blood vessels to prevent unexplained, recurrent miscarriages; Prevent thromboembolic events in cancer patients receiving chemotherapy
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,200.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today